

Recombinant Human Galectin-8/LGALS8 Protein (GST Tag)

Catalog No. PKSH031698

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Synonyms	Galectin-8;Gal-8;Po66 Carbohydrate-Binding Protein;Po66-CBP;Prostate Carcinoma Tumor Antigen 1;PCTA-1;LGALS8
Species	Human
Expression Host	E.coli
Sequence	Met 1-Trp 317
Accession	AAF19370.1
Calculated Molecular Weight	62.7 kDa
Observed molecular weight	60 kDa
Tag	N-GST
Bioactivity	Measured by its ability to agglutinate human red blood cells. The ED50 for this effect is typically 0.2-1 µg/ml.

Properties

Purity	> 76 % as determined by reducing SDS-PAGE.
Endotoxin	Please contact us for more information.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from sterile 50mM Tris, 0.1 M NaCl, pH 8.0 Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 76 % as determined by reducing SDS-PAGE.

Background

For Research Use Only

Galectin-1 (Gal-1, GAL1), is a member of the galectins, a family of animal lectins ranging from *Caenorhabditis elegans* to humans, which is defined by their affinity for beta-galactosides and by significant sequence similarity in the carbohydrate-binding site. It is a homodimer with a subunit molecular mass of 14.5 kDa, which contains six cysteine residues per subunit. The cysteine residues should be in a free state in order to maintain a molecular structure that is capable of showing lectin activity. This endogenous lectin widely expressed at sites of inflammation and tumour growth, has been postulated as an attractive immunosuppressive agent to restore immune cell tolerance and homeostasis in autoimmune and inflammatory settings. On the other hand, galectin-1 contributes to different steps of tumour progression including cell adhesion, migration and tumour-immune escape, suggesting that blockade of galectin-1 might result in therapeutic benefits in cancer. Several potential glycoprotein ligands for galectin-1 have been identified, including lysosome-associated membrane glycoproteins and fibronectin, laminin, as well as T-cell glycoproteins CD43 and CD45. Evidence points to Gal-1 and its ligands as one of the master regulators of such immune responses as T-cell homeostasis and survival, T-cell immune disorders, inflammation and allergies as well as host-pathogen interactions.